Ariceum Therapeutics receives FDA’s Orphan Drug Designation for targeted radionuclide cancer treatment

Ariceum Therapeutics (Ariceum), a private biotech company developing radiopharmaceutical products for the diagnosis and treatment of certain hard-to-treat cancers, today announced that the U.S. Food and Drug Administration (FDA) has…

Continue ReadingAriceum Therapeutics receives FDA’s Orphan Drug Designation for targeted radionuclide cancer treatment